Odyssey Health, Inc.
For the period ended Apr 30, 2025. Filed Jun 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2025 · Filed Jun 13, 2025
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Shares | Dollars | Capital | Deficit | (Deficit) | |
| Balances, July 31, 2024 | 96,709,763 | $96,710 | $55,572,687 | $(61,003,146) | $(5,333,749) |
| Stock-based compensation | – | – | 60,487 | – | 60,487 |
| Warrants issued in debt financing | – | – | 13,343 | – | 13,343 |
| Net loss | – | – | – | (1,018,906) | (1,018,906) |
| Balances, October 31, 2024 | 96,709,763 | 96,710 | 55,646,517 | (62,022,052) | (6,278,825) |
| Stock-based compensation | – | – | 36,131 | – | 36,131 |
| Net loss | – | – | – | (220,126) | (220,126) |
| Balances, January 31, 2025 | 96,709,763 | 96,710 | 55,682,648 | (62,242,178) | (6,462,820) |
| Stock-based compensation | – | – | 11,781 | – | 11,781 |
| Net loss | – | – | – | (251,743) | (251,743) |
| Balances, April 30, 2025 | 96,709,763 | $96,710 | $55,694,429 | $(62,493,921) | $(6,702,782) |
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Shares | Dollars | Capital | Deficit | (Deficit) | |
| Balances, July 31, 2023 | 79,067,879 | $79,068 | $53,862,378 | $(60,097,375) | $(6,155,929) |
| Stock-based compensation | – | – | 322,728 | – | 322,728 |
| Common stock issued in debt financing | 655,792 | 656 | 78,039 | – | 78,695 |
| Common stock issued in equity financings | 500,000 | 500 | 45,320 | – | 45,820 |
| Warrants exercised in connection with debt financing | 1,610,390 | 1,610 | (1,610) | – | – |
| Warrants issued in debt financing | – | – | 28,448 | – | 28,448 |
| Return of shares | (100,000) | (100) | 100 | – | – |
| Net loss | – | – | – | (538,035) | (538,035) |
| Balances, October 31, 2023 | 81,734,061 | 81,734 | 54,335,403 | (60,635,410) | (6,218,273) |
| Stock-based compensation | – | – | 677,391 | – | 677,391 |
| Restricted stock units issued | 1,500,000 | 1,500 | (1,500) | – | – |
| Common stock issued in debt financing | 11,098,989 | 11,100 | 912,828 | – | 923,928 |
| Common stock issued in equity financings | 100,000 | 100 | 9,700 | – | 9,800 |
| Deemed dividend - warrants | – | – | 63,455 | (63,455) | – |
| Net income | – | – | – | 13,277,566 | 13,277,566 |
| Balances, January 31, 2024 | 94,433,050 | 94,434 | 55,997,277 | (47,421,299) | 8,670,412 |
| Stock-based compensation | – | – | 51,483 | – | 51,483 |
| Warrants exercised in connection with debt financing | 1,926,713 | 1,926 | (1,926) | – | – |
| Net loss | – | – | – | (842,341) | (842,341) |
| Balances, April 30, 2024 | 96,359,763 | $96,360 | $56,046,834 | $(48,263,640) | $7,879,554 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.